Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study

NCT05447260 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT05447260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05447260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis: a Multicenter, Prospective, Single-arm Clinical Study
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 4
Overall status
Unknown status
Start date
June 10, 2022
Completion date
December 10, 2023
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis